Showing 1971-1980 of 5627 results for "".
- FCI Ophthalmics Announces Availability of EzyPor Polyethylene Orbital Implanthttps://modernod.com/news/fci-ophthalmics-announces-availability-of-ezypor-polyethylene-orbital-implant/2481336/FCI Ophthalmics announced the launch of EzyPor in the United States. EzyPor is a high density polyethylene orbital implant with a patented suturing platform, indicated for enucleation, evisceration, and secondary implantation. Ezyor is designed to have a smooth
- High-Tech Imaging Offers New Way to Detect Signs of Early Glaucomahttps://modernod.com/news/high-tech-imaging-offers-new-way-to-detect-signs-of-early-glaucoma/2481008/A new, noninvasive ocular imaging method may be able to detect an early indicator of glaucoma in time to prevent disease progression and vision loss, according to a new study from New York Eye and Ear Infirmary of Mount Sinai (NYEE). The study was published in the July/August issue of Op
- Yuyu Pharma Announces First Patient Enrolled in Phase 2 Study of YP-P10 Ophthalmic Solution for the Treatment of Dry Eye Diseasehttps://modernod.com/news/yuyu-pharma-announces-first-patient-enrolled-in-phase-2-clinical-study-evaluating-yp-p10-ophthalmic-solution-for-the-treatment-of-dry-eye-disease/2480996/Yuyu Pharma announced the enrollment of the first patient in a phase 2 clinical study evaluating YP-P10, a novel and patented synthetic peptide with anti-inflammatory and wound healing properties being investigated to treat patients with dry eye disease (DED). Yuyu received cl
- Apellis Presents New Phase 3 DERBY and OAKS Data of Intravitreal Pegcetacoplan for GAhttps://modernod.com/news/apellis-presents-new-phase-3-derby-and-oaks-data-of-intravitreal-pegcetacoplan-for-ga/2480970/Apellis Pharmaceuticals announced that five oral presentations and two on-demand papers are being highlighted at the American Society of Retina Specialists Annual Scientific Meeting taking place July 13 -16, 2022 in New York City. New data include
- Genentech: New 2-Year Data Confirm Vabysmo Improves Vision With Fewer Treatments for Wet AMDhttps://modernod.com/news/genentech-new-two-year-data-confirm-vabysmo-improves-vision-with-fewer-treatments-for-people-with-wet-amd/2480965/Genentech announced new 2-year data from the TENAYA and LUCERNE studies that reinforce the long-term efficacy, safety and durability of Vabysmo (faricimab-svoa) in wet age-related macular degeneration (AMD). The 2-year data were presented at the 2022 American Society of Retina Specialis
- Novartis Acquires Kedalion Therapeutics and its Ocular Delivery Platformhttps://modernod.com/news/novartis-acquires-kedalion-therapeutics-and-its-ocular-delivery-platform/2480952/Novartis announced that it has acquired Kedalion Therapeutics and its AcuStream technology, a device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye.1,2 Terms of the deal were
- Opus Genetics Appoints Ben Yerxa, PhD, as Permanent Chief Executive Officerhttps://modernod.com/news/opus-genetics-appoints-ben-yerxa-phd-as-permanent-chief-executive-officer/2480923/Opus Genetics announced the appointment of Ben Yerxa, PhD, as Chief Executive Officer. Dr. Yerxa previously served as acting CEO of Opus, in addition to former roles as CEO of the Foundation Fighting Blindness and the Retinal Degeneration (RD) Fund, the venture arm of th
- Verana Health Report Shows a More Than 80% Glaucoma Surgery Uptake Over 8-Year Periodhttps://modernod.com/news/verana-health-unveils-annual-ophthalmic-industry-report-that-shows-a-more-than-80-glaucoma-surgery-uptake-over-8-year-period-1/2480818/Verana Health announced the release of its American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) Industry Report for 2021 at the ASCRS annual meeting. The report provides 8 years of detailed ophthalmic insights generated through analysis of the data contained i
- Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)https://modernod.com/news/kiora-pharmaceuticals-granted-orphan-drug-designation-for-kio-301-an-investigational-drug-for-the-treatment-of-retinitis-pigmentosa-rp/2480706/Kiora Pharmaceuticals has received orphan drug designation from the FDA for its investigational treatment of retinitis pigmentosa, KIO-301. Kiora expects to initiate clinical trials of KIO-301 in Q3 2022. Orphan drug designation provides for facilitated development discussions with the FDA,
- New 2-Year Data for Genentech’s Vabysmo and Susvimo Show Potential of Fewer Treatments for People With Wet AMD and DMEhttps://modernod.com/news/new-2-year-data-for-genentechs-vabysmo-and-susvimo-reinforce-potential-to-maintain-vision-with-fewer-treatments-for-people-with-wet-amd-and-dme/2480631/Genentech announced that new 2-year data from its phase 3 studies of Vabysmo (faricimab-svoa) and Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant will be presented at Angiogenesis, Exudation and Degeneration 2022 on February 12. These longer-term r